Management of nodal diffuse large B-cell lymphomas: Practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation

Haematologica

Volumn 91, Issue 1, 2006, Pages 96-103

  Barosi, Giovanni ^a   Carella, Angelo ^b   Lazzarino, Mario ^a   Marchetti, Monia ^a,c   Martelli, Maurizio ^a,c   Rambaldi, Alessandro ^d   Tarella, Corrado ^e   Vitolo, Umberto ^e   Zinzani, Pier Luigi ^f   Tura, Sante ^f  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Divisione di Ematologia   (Italy)

^e MOLINETTE HOSPITAL   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Chemotherapy; Clinical practice guidelines; Non Hodgkins lymphoma; Rituximab; Systematic review

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CLINICAL TRIAL; CONSENSUS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; MEDICAL SOCIETY; NONHODGKIN LYMPHOMA; PRACTICE GUIDELINE; PROGNOSIS;

ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ITALY; LYMPH NODES; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE;

EID: 32544438620     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Masala C, Di Lollo S, Picoco C, Crosignani P, Demicheli V, Fontana A, et al. Incidence rates of leukemias, lymphomas and myelomas in Italy: geographic distribution and NHL histotypes. Int J Cancer 1996;68:156-9.
2. Groves FD, Linet MS, Travis LB, et al. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000;92:1240-51.
3. Varterasian ML, Graff JJ, Severson RK, Weiss L, al-Katib AM, Kalemkerian GP. Non-Hodgkin's lymphoma: an analysis of the Metropolitan Detroit SEER database. Cancer Invest 2000;8: 303-8.
4. Jerkeman M, Anderson H, Dictor M, Kvaløy S, Akerman M, Cavallin-Stahl E. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma. A Nordic Lymphoma Group study. Ann Hematol 2004;83:414-9.
5. Barosi G, Carella A, Lazzarino M, Marchetti M, Martelli M, Rambaldi A, et al. Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica 2005;90:1236-57.
6. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001;323:334-6.
7. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6.
8. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 2003;329:987-94.
9. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
10. Vaughan Hudson B, Vaughan Hudson G, LacLennan KA, Anderson L, Linch DC. Clinical stage I non-.Hodgkin's lymphoma: long term follow up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 1994;69:1088-93
11. Nissen NI, Ersboll J, Hansen HS, Walbom-Jorgensen S, Pedersen- Bjergaard J, Hansen MM, et al. A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas. Cancer 1983;52:1-7.
12. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21-6.
13. Horning SJ, Weller E, Kim K, Earle JD, O'Connell MJ, Habermann TM, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004;22:3032-8.
14. Miller TP, Leblanc M, Spier C, Chase E, Fischer RI. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial. Blood 2001;98:724a-725a [Abstract 3024].
15. Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005;352:1197-205.
16. Bonnet C, Fillet G, Mounier N, Thieblemont C, Freme C, Quensel B, et al. Radiotherapy is unnecessary in elderly patients with localized aggressive non Hodgkin lymphoma: results of the LNH93-4 study. Ann Oncol 2002;13: Suppl 27[Abstract].
17. Tilly E, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003;102:4284-9.
18. Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. J Clin Oncol 1995;13:2916-23.
19. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626-33
20. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634-41.
21. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
22. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279-84.
23. Feugier P, Van hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long term results of the R-CHOP stsudy in the treatment of elderly patients with diffuse large B-cell lymphoma: a stsudy by the Group d'étude des lymphomes de l'adulte. J Clin Oncol 2005.
24. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-33
25. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Benyunes M, et al. Long terni follow-Up of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin's lymphoma (NHL). Blood 2002;100:360a. [Abstract 1396].
26. Pfreundschuh MG, Trumper L, Ma D, Osterborg A, Pettengell R, Trneny M, et al. Randomized intergroup trial of first line treatment for aptoents <=60 years with diffuse large B-cell npn Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab - early stopping after the first interim analysis. ASCO 2004: [Abstract 6500].
27. Greb A, JBohlius J, Schiefer D, Schwarzer G, Engert A. Meta-analysis of randomised trials comparing high-dose chemotherapy with autologous stem cell support as part of first-line therapy with conventional chemotherapy in aggressive non-Hodgkin lymphoma - first results. Blood 2003;102:734a. [Abstract 2712].
28. Strehl J, Mey U, Glasmacher A, Djulbegovic B, Mayr C, Gorschluter M, et al. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica 2003;88:1304-15.
29. Vitolo U, Liberati AM, Cabras MG, Federico M, Angelucci E, et al. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy Mega-CEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial. Haematologica 2006;90:793-801.
30. Aviles A, Delgado S, Nambo MJ, Alatriste S, Diaz-Maqueo JC. Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma. Int J Radiat Oncol Biol Phys 1994;30:799-803.
31. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287-95.
32. Bos GM, van Putten WL, van der Holt B, van den Bent M, Verdonck LF, Hagenbeek A. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group. Ann Oncol 1998;9:191-4.
33. Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002;13:1099-107.
34. Zinzani PL, Magagnoli M, Chierichetti F, Zompatori M, Garraffa G, Bendandi M, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999;10:1181-4.
35. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002;43:1018-27.
36. Hong SP, Hahn JS, Lee JD, Bae SW, Youn MJ. 18F-fluorodeoxyglucose- positron emission tomography in the staging of malignant lymphoma compared with CT and 67Ga scan. Yonsei Med J 2003;44:779-86.
37. Carr R, Barrington SF, Madan B, O'Doherty MJ, Saunders CA, van der Walt J, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91:3340-6.
38. Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 2000; 18:3633-42.
39. Olivieri A, Brunori M, Capelli D, Montanari M, Massidda D, Gini G, et al. Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. Eur J Haematol 2004;72:10-7
40. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5.
41. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, et al. Rituximab and ICE (RICE) as second-line therapy prior to autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103:3684-8.
42. Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D, et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003; 102:1989-96.
43. Haioun C, Mounier N, Emile JF, Feugier P, Coiffier B, Tilly H, et al. Rituximab vs. nothing after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor risk diffuse large B-cell lymphoma. Results of the First Interim Analysis of the Randomized LNH98-B3 CELA Study. Blood 2003;102:399a. [Abstract 1447].
44. Bertz H, Illerhaus G, Veelken H, Finke J. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens. Ann Oncol 2002; 13:135-9.
45. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100:4310-6.
46. www.agreecollaboration.com (accessed on February 2005).
47. Shiffman RN, Shekelle P, Overhage M, Slutcky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med 2003;139: 493-8.
48. Cancer Care Ontario Guidelines, www.cancercare.org (Accessed December 2003).
49. British Columbia Cancer Agency. Lymphoma guidelines. http://www.bccancer. bc.ca/HPI/ CancerManagementGuidelines/Lymphoma/d efault.htm (accessed December 2003).
50. th May 2004).
51. Hiddemann W. ESMO (European Society for Medical Oncology) Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed follicular lymphoma. Ann Oncol 2003;14:1163-4.
52. th May 2004.
53. Lister A, Abrey LE, Sandlund JT. Central nervous system lymphoma. Hematology 2002: 283-96.
54. Messori A, Bonistalli L, Costantini M, Alterini R. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 1997;19:275-81.
55. Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer 2005;103:1644-51.
56. Groot MT, Lugtenburg PJ, Hornberger J, Huijgens PC, Uyl-de Groot CA. Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands. Eur J Haematol 2005;74:194-202.